Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 10/20 | 0.50 |
| ▸ | TSHR | P16473 | 9/20 | 0.50 |
| ▸ | HPGD | P15428 | 7/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | SELL | P14151 | 1/20 | 0.42 |
| ▸ | SELP | P16109 | 1/20 | 0.42 |
| ▸ | SELE | P16581 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11384008 | 0.82 | HSD17B10 (0.52) | HSD17B10TSHRHPGDCYP3A4HSP90AA1 | |
| SCHEMBL26018812 | 0.82 | HSD17B10 (0.43) | HSD17B10TSHRHPGDCYP3A4HSP90AA1 | |
| SCHEMBL13997274 | 0.82 | HSD17B10 (0.59) | HSD17B10TSHRHPGDCYP3A4HSP90AA1 | |
| SCHEMBL10592132 | 0.82 | HSD17B10 (0.59) | HSD17B10TSHRHPGDCYP3A4HSP90AA1 | |
| SCHEMBL7023508 | 0.80 | HSD17B10 (0.44) | HSD17B10TSHRHPGDCYP3A4HSP90AA1 | |
| SCHEMBL157574 | 0.80 | SIRT1 (0.48) | HSD17B10TSHRHPGDCYP3A4HSP90AA1 | |
| SCHEMBL212921 | 0.80 | HSD17B10 (0.55) | HSD17B10TSHRHPGDCYP3A4HSP90AA1 | |
| SCHEMBL22138546 | 0.77 | HSD17B10 (0.59) | HSD17B10TSHRHPGDCYP3A4HSP90AA1 | |
| SCHEMBL4450834 | 0.77 | HSD17B10 (0.43) | HSD17B10TSHRHPGDCYP3A4HSP90AA1 | |
| SCHEMBL7630509 | 0.76 | HSD17B10 (0.44) | HSD17B10TSHRHPGDCYP3A4HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101395165-A | Ligand, method for preparing the same and catalyst using the same | UNIV TOKYO (JP) | 2009-03-25 | — | — | CN | disclosed |
| EP-1349856-B1 | ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| EP-1349856-A2 | ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-08 | — | — | EP | disclosed |
| US-6613942-B1 | Nonpeptide; 4-hydroxy benzoic acid hydrazides | NOVO NORDISK A/S (DK) | 2003-09-02 | — | — | US | disclosed |
| US-6482951-B2 | ISOINDOLIN-1-ONE-SUBSTITUTED PROPIONAMIDE GLUCOKINASE ACTIVATORS WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020082260-A1 | Isoindolin-1-one glucokinase activators | GUERTIN KEVIN RICHARD (US) | 2002-06-27 | — | — | US | disclosed |
| WO-2002048106-A2 | ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
| US-4558129-A | Benzodioxanyl-hydroxyethylene-piperazinyl acetanilides which effect calcium entry and β-blockade | SYNTEX (U.S.A.) INC. (US) | 1985-12-10 | — | — | US | disclosed |
| US-4499100-A | CARDIOUVASCULAR DISORDERS | SYNTEX (U.S.A.) INC. (US) | 1985-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082260-A1 | Isoindolin-1-one glucokinase activators | GCKR, GCK, PGK2 | HSD17B10 2317/4885TSHR 3783/4885HPGD 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.